866-997-4948(US-Canada Toll Free)

Miripla Analysis and Market Forecasts from 2010 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 20 Pages


GlobalDatas pharmaceuticals report, Miripla Analysis and Market Forecasts from 2010 to 2020 provides Miripla sales estimates for Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2010-2020). The report also includes information on Liver Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope
  • Therapy area profile including patient population for Japan
  • Analysis and review of Miripla including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Miripla including efficacy, safety, pricing and other details which influence its sales potential
  • Detailed sales forecast for 2010-2020 for Miripla in Japan
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of content

1 Table of contents
1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Liver Cancer Market 4
2.2 Epidemiology 4
2.3 Etiology 5
2.3.1 Hepatitis B Infection 5
2.3.2 Hepatitis C Infection 5
2.3.3 Alcohol 5
2.3.4 Aflatoxin B1 6
2.3.5 Hemochromatosis 6
2.3.6 Diabetes and Obesity 6
2.3.7 Cirrhosis 6
2.4 GlobalData Report Guidance 6

3 Liver Cancer : Market Characterization 7
3.1 Liver Cancer Market 7
3.2 Liver Cancer Market Forecasts and CAGR 7
3.3 Drivers for the Liver Cancer Market 7
3.3.1 High Incidence 8
3.3.2 High Mortality 8
3.3.3 Large Unmet Need 9

4 TumorNodeMetastases (TNM) Classification of Liver Cancer 10

5 Miripla 11
5.1 Introduction 11
5.2 Mechanism of Action 11
5.3 Clinical Studies 11
5.3.1 Phase II/III Trials 11
5.3.2 Phase II Trials 11
5.3.3 Phase I Trials 11
5.4 Approval History of Miripla 12
5.5 Factors Affecting Sales of Miripla 12
5.5.1 Method of Administration 12
5.5.2 Low Competition 12
5.5.3 Lack of Presence in the US and EU Market 12
5.6 Drug Risk Benefit Score 12
5.6.1 Efficacy 13
5.6.2 Safety 13
5.6.3 Compliance 13
5.6.4 Dosing Convenience 13
5.7 Intensity of Competition 13
5.8 Sales Forecast 13
5.8.1 Target Patient Pool of Miripla 13
5.8.2 Dosing 14
5.8.3 Market Penetration 14
5.8.4 Annual Cost of Therapy 14
5.8.5 Sales Projections of Miripla 15

6 Liver Cancer Market: Appendix 16
6.1 Market Definitions 16
6.2 List of Abberiviations 16
6.3 Research Methodology 16
6.3.1 Coverage 16
6.3.2 Secondary Research 16
6.3.3 Forecasting 17
6.3.4 Number of Patients Approved to take the Drug 17
6.3.5 Net Penetration of Drug 18
6.3.6 Net Annual Dosing 18
6.3.7 Annual Cost of Therapy 18
6.3.8 Primary Research 18
6.3.9 Expert Panels 19
6.4 Drug Sales Estimates Model 19
6.5 Contact Us 19
6.6 Disclaimer 19
6.7 Sources 20

List of Table


Table 1: Liver Cancer, Incidences and Mortality, 20082030 4
Table 2: Drug Risk Benefit Score of Miripla 12
Table 3: Miripla, Liver Cancer, Japan, Estimated Sales ($m), 20102020 15

List of Chart


Figure 1: Fatality = [(% Distribution of Incidence) (% Distribution Mortality )] of Most Common Cancers 5
Figure 2: Liver Cancer, Global, Market Size Forecast ($m), 20102020 7
Figure 3: Liver Cancer, Worldwide, Incidence (in millions), 20082030 8
Figure 4: Oncology, Worldwide, Incidence (in millions), 20082030 8
Figure 5: Liver Cancer, Worldwide, Mortality (in millions), 20082030 9
Figure 6: Classification of Liver Cancer 10
Figure 7: Drug Model Diagram of Miripla 14
Figure 8: Miripla, Liver Cancer, Japan, Estimated Sales ($m), 20102020 15
Figure 9: Drug Model Diagram 17
Figure 10: Patients Approved for the Drug 18

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *